At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 target
Drug / intervention
Marinol (Dronabinol) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study
In Brief
A Phase 2 clinical trial evaluating Marinol (Dronabinol) and Placebo for Cancer and 3 related conditions. Completed, enrolled 80 participants across 2 sites.
Detailed Summary
To investigate delta-9-tetrahydrocannabinol's (THC) ability to increase food intake and improve food enjoyment for advanced cancer patients with taste and/or smell (chemosensory) abnormalities.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Anorexia, Taste Disorders, Olfactory Disorders
CountriesCanada
CollaboratorsUniversity of Alberta
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2006
Enrollment StartAug 2006
Study CompletionNov 2009
TodayJul 2026
First PostedApr 21, 2006
Enrollment StartAug 1, 2006
Study CompletionNov 1, 2009
TodayJul 2, 2026
Posted 20.2 years ago
Interventions
Marinol (Dronabinol)drug
Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
Placeboother